Net Income

FinTech leader Derivative Path promotes Zack Nagelberg to President, signaling a strategic push into AI-driven risk management for evolving capital markets.

Princeton NuEnergy hires a battery industry titan to spearhead its commercial push, aiming to dominate the booming U.S. battery recycling market.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

The suburban office REIT has extended key debt maturities and lowered borrowing costs, signaling lender confidence and positioning it for strategic growth.

With its stock at an all-time high, Element Solutions Inc. faces investors as its specialty chemicals fuel the booming electronics and EV markets.

After a volatile market debut, the supersonic flight company hits the NYSE, signaling a new era for high-speed testing and air-launch services.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

Five Alberta First Nations launch a legal challenge against a federal-provincial deal, citing a lack of consent for the world's largest proposed CCS project.

The safety science giant posted record 2025 earnings and a strong 2026 outlook, sharpening its focus on high-growth tech with a key divestiture.

Auto parts giant LKQ Corporation explores a potential sale after 2025 profits fall, despite strong cash flow and a new restructuring plan.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

Supremex reports strong Q4 growth driven by its packaging division, erasing nearly all debt and positioning itself for an aggressive future beyond envelopes.

At a major scientific conference, Seer Inc.'s Proteograph platform is taking center stage, promising deeper insights into Alzheimer's and heart disease.

AmpliTech launches mid-band 5G radios, aiming to accelerate Open RAN adoption and capture a slice of the booming private network and smart city market.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

New data shows an AI-driven approach is enrolling IBD patients 3.4x faster, promising to accelerate the delivery of novel therapies to those in need.

With a new $50M facility from CIBC, Montreal-based AlayaCare is poised to accelerate its M&A strategy and advance its mission to digitize home care.

Specialist asset manager Sprott Inc. leverages a volatile market and geopolitical tensions, riding a precious metals boom to record profits and AUM growth.

Amid regional conflict, InterCure reports NIS 265M revenue, enters German market, and makes strategic US moves, showcasing remarkable resilience and growth.

With BRINSUPRI revenues set to hit $1B, Insmed is pouring cash into a high-stakes pipeline. Can it outrun its massive burn rate to deliver the next breakthrough?